Predictive significance of surgery-induced lymphopenia on the survival after curative resection for locally advanced gastric cancer: a retrospective cohort analysis

被引:2
作者
Aizawa, Masaki [1 ]
Yabusaki, Hiroshi [1 ]
Matsuki, Atsushi [1 ]
Bamba, Takeo [1 ]
Nakagawa, Satoru [1 ]
机构
[1] Niigata Canc Ctr Hosp, Dept Digest Surg, 2-15-3 Kawagishicho, Niigata, Niigata 9518566, Japan
关键词
Gastric cancer; Prognosis; Postoperative inflammatory response; Lymphocyte; CELLS; COMPLICATIONS; CHEMOTHERAPY;
D O I
10.1186/s12957-023-02887-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundFollowing the establishment of the anti-cancer effect of immune checkpoint inhibitors, lymphopenia has attracted attention as a parameter of preexisting cancer-related immune tolerance. Although the pretreatment absolute lymphocyte count (ALC) has been reported as a prognostic factor in gastric cancer patients, the impact of perioperative changes in the ALC remains unknown. The aim of the present study was to explore the relationship between surgery-induced lymphopenia and outcome.MethodsDatabase entries for 584 patients who underwent curative resections for pathological Stage IB-III gastric cancer were reviewed. We retrospectively compared clinicopathological factors including pretreatment ALC (pre-ALC) and ALC at first visit after discharge (post-ALC) with the survival. The low ALC was defined as < 1000/mu L.ResultsThe ALC decreased significantly at 1 and 3 days after surgery and then recovered to the baseline value. A low pre-ALC (p < 0.001) and a low post-ALC (p < 0.001) were both correlated with a poor relapse-free survival (RFS). A multivariate analysis of RFS identified a low post-ALC (hazard ratio 1.875, 95% CI 1.156-3.402, p = 0.01), age, gender, BMI, T disease, N disease, severe vessel invasion, type of gastrectomy and postoperative morbidity as independent factors. The low post-ALC group had a poor RFS among patients with Stage II (p = 0.04) and Stage III (p = 0.04) disease, but not among patients with Stage IB disease (p = 0.13). Consistently, the overall survival (OS) rate was significantly lower among patients with a low post-ALC for all stage (p < 0.001), stage II (p = 0.02) and stage III (p = 0.01) disease, not for stage IB (p = 0.09). A low post-ALC was identified as an independent factor for predicting OS by multivariate analysis (hazard ratio: 2.275, 95% CI 1.373-3.769, p = 0.01).ConclusionsA decrease in post-ALC was correlated with both of RFS and OS after curative resection in patients with locally advanced gastric cancer.
引用
收藏
页数:11
相关论文
共 39 条
  • [1] KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer
    Bang, Yung-Jue
    Van Cutsem, Eric
    Fuchs, Charles S.
    Ohtsu, Atsushi
    Tabernero, Josep
    Ilson, David H.
    Hyung, Woo Jin
    Strong, Vivian E.
    Goetze, Thorsten Oliver
    Yoshikawa, Takaki
    Tang, Laura H.
    Hwang, Peggy May Tan
    Webb, Nancy
    Adelberg, David
    Shitara, Kohei
    [J]. FUTURE ONCOLOGY, 2019, 15 (09) : 943 - 952
  • [2] Sir Isaac Newton, sepsis, SIRS, and CARS
    Bone, RC
    [J]. CRITICAL CARE MEDICINE, 1996, 24 (07) : 1125 - 1128
  • [3] Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy
    Ceze, N.
    Thibault, G.
    Goujon, G.
    Viguier, J.
    Watier, H.
    Dorval, E.
    Lecomte, T.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (05) : 1305 - 1313
  • [4] Inflammation and cancer
    Coussens, LM
    Werb, Z
    [J]. NATURE, 2002, 420 (6917) : 860 - 867
  • [5] Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer
    De Giorgi, Ugo
    Mego, Michal
    Scarpi, Emanuela
    Giuliano, Mario
    Giordano, Antonio
    Reuben, James M.
    Valero, Vicente
    Ueno, Naoto T.
    Hortobagyi, Gabriel N.
    Cristofanilli, Massimo
    [J]. CLINICAL BREAST CANCER, 2012, 12 (04) : 264 - 269
  • [6] Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
    Fuchs, Charles S.
    Doi, Toshihiko
    Jang, Raymond W.
    Muro, Kei
    Satoh, Taroh
    Machado, Manuela
    Sun, Weijing
    Jalal, Shadia I.
    Shah, Manish A.
    Metges, Jean-Phillipe
    Garrido, Marcelo
    Golan, Talia
    Mandala, Mario
    Wainberg, Zev A.
    Catenacci, Daniel V.
    Ohtsu, Atsushi
    Shitara, Kohei
    Geva, Ravit
    Bleeker, Jonathan
    Ko, Andrew H.
    Ku, Geoffrey
    Philip, Philip
    Enzinger, Peter C.
    Bang, Yung-Jue
    Levitan, Diane
    Wang, Jiangdian
    Rosales, Minori
    Dalal, Rita P.
    Yoon, Harry H.
    [J]. JAMA ONCOLOGY, 2018, 4 (05)
  • [7] Hallmarks of Cancer: The Next Generation
    Hanahan, Douglas
    Weinberg, Robert A.
    [J]. CELL, 2011, 144 (05) : 646 - 674
  • [8] Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas
    Ho, Won Jin
    Yarchoan, Mark
    Hopkins, Alex
    Mehra, Ranee
    Grossman, Stuart
    Kang, Hyunseok
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [9] Surgery induced immunosuppression
    Hogan, Brian V.
    Peter, Mark B.
    Shenoy, Hrishikesh G.
    Horgan, Kieran
    Hughes, Thomas A.
    [J]. SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND, 2011, 9 (01): : 38 - 43
  • [10] Japanese Gastric Cancer Association, 2017, GASTRIC CANCER, V15, DOI DOI 10.1007/s10120-011-0041-5